Compare Stocks: BBNX, PLSE, LMAT, and AXGN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXGN AxoGen	$42.21 +2.1%	$42.13	$12.39 ▼ $46.95	$2.27B	1.09	1.25 million shs	1.22 million shs
BBNX Beta Bionics	$12.83 -10.1%	$14.99	$8.80 ▼ $32.71	$577.22M	3.04	1.08 million shs	2.00 million shs
LMAT LeMaitre Vascular	$101.32 -0.9%	$97.15	$79.00 ▼ $118.01	$2.32B	0.52	264,621 shs	234,188 shs
PLSE Pulse Biosciences	$35.13 +0.3%	$27.65	$12.56 ▼ $36.78	$2.43B	1.65	349,314 shs	277,942 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXGN AxoGen	+2.08%	+6.89%	-4.11%	-2.47%	+219.77%
BBNX Beta Bionics	-10.09%	-19.05%	-23.17%	+24.68%	-23.45%
LMAT LeMaitre Vascular	-0.85%	+5.99%	+2.61%	-9.57%	+23.61%
PLSE Pulse Biosciences	+0.26%	+16.21%	+24.00%	+68.65%	+138.49%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXGN AxoGen	$42.21 +2.1%	$42.13	$12.39 ▼ $46.95	$2.27B	1.09	1.25 million shs	1.22 million shs
BBNX Beta Bionics	$12.83 -10.1%	$14.99	$8.80 ▼ $32.71	$577.22M	3.04	1.08 million shs	2.00 million shs
LMAT LeMaitre Vascular	$101.32 -0.9%	$97.15	$79.00 ▼ $118.01	$2.32B	0.52	264,621 shs	234,188 shs
PLSE Pulse Biosciences	$35.13 +0.3%	$27.65	$12.56 ▼ $36.78	$2.43B	1.65	349,314 shs	277,942 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXGN AxoGen	+2.08%	+6.89%	-4.11%	-2.47%	+219.77%
BBNX Beta Bionics	-10.09%	-19.05%	-23.17%	+24.68%	-23.45%
LMAT LeMaitre Vascular	-0.85%	+5.99%	+2.61%	-9.57%	+23.61%
PLSE Pulse Biosciences	+0.26%	+16.21%	+24.00%	+68.65%	+138.49%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXGN AxoGen	2.73	Moderate Buy	$51.00	20.82% Upside
BBNX Beta Bionics	2.55	Moderate Buy	$20.10	56.66% Upside
LMAT LeMaitre Vascular	2.56	Moderate Buy	$112.60	11.13% Upside
PLSE Pulse Biosciences	2.50	Moderate Buy	$32.33	-7.96% Downside

Current Analyst Ratings Breakdown

Latest BBNX, PLSE, LMAT, and AXGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/30/2026	AXGN AxoGen	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$50.00 ➝ $53.00
7/30/2026	AXGN AxoGen	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
7/30/2026	AXGN AxoGen	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$55.00
7/30/2026	AXGN AxoGen	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$50.00 ➝ $55.00
7/30/2026	AXGN AxoGen	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Market Outperform	$50.00 ➝ $55.00
7/29/2026	AXGN AxoGen	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$55.00
7/28/2026	PLSE Pulse Biosciences	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
7/28/2026	PLSE Pulse Biosciences	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$35.00
7/28/2026	BBNX Beta Bionics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$22.00
7/21/2026	LMAT LeMaitre Vascular	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
7/17/2026	BBNX Beta Bionics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 8/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXGN AxoGen	$225.21M	10.08	N/A	N/A	$4.77 per share	8.85
BBNX Beta Bionics	$100.25M	5.76	N/A	N/A	$5.70 per share	2.25
LMAT LeMaitre Vascular	$249.60M	9.28	$2.90 per share	34.91	$17.35 per share	5.84
PLSE Pulse Biosciences	$350K	6,946.71	N/A	N/A	$1.19 per share	29.52

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXGN AxoGen	-$15.70M	-$0.64	N/A	156.33	N/A	-13.36%	-8.90%	-6.47%	N/A
BBNX Beta Bionics	-$73.20M	-$1.65	N/A	N/A	N/A	-61.31%	-26.30%	-23.25%	N/A
LMAT LeMaitre Vascular	$57.73M	$2.71	37.39	30.98	2.81	24.35%	15.36%	9.78%	8/4/2026 (Estimated)
PLSE Pulse Biosciences	-$72.78M	-$1.10	N/A	N/A	N/A	N/A	-86.67%	-73.61%	8/6/2026 (Confirmed)

Latest BBNX, PLSE, LMAT, and AXGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	PLSE Pulse Biosciences	-$0.2933	N/A	N/A	N/A	$0.53 million	N/A
8/4/2026	Q2 2026	LMAT LeMaitre Vascular	$0.8070	N/A	N/A	N/A	$71.47 million	N/A
7/29/2026	Q2 2026	AXGN AxoGen	$0.1214	$0.12	-$0.0014	-$0.03	$67.10 million	$69.73 million
7/29/2026	Q2 2026	BBNX Beta Bionics	-$0.62	-$0.53	+$0.09	-$0.53	N/A	$32.01 million
5/5/2026	Q1 2026	LMAT LeMaitre Vascular	$0.66	$0.68	+$0.02	$0.68	$66.67 million	$66.55 million
5/4/2026	Q1 2026	PLSE Pulse Biosciences	-$0.32	-$0.27	+$0.05	-$0.27	$0.25 million	$0.40 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXGN AxoGen	N/A	N/A	N/A	N/A	N/A
BBNX Beta Bionics	N/A	N/A	N/A	N/A	N/A
LMAT LeMaitre Vascular	$1.00	0.99%	+16.05%	36.90%	14 Years
PLSE Pulse Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXGN AxoGen	0.07	6.60	5.33
BBNX Beta Bionics	N/A	8.88	9.67
LMAT LeMaitre Vascular	0.42	14.32	12.20
PLSE Pulse Biosciences	N/A	7.26	7.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXGN AxoGen	80.29%
BBNX Beta Bionics	N/A
LMAT LeMaitre Vascular	84.64%
PLSE Pulse Biosciences	76.95%

Insider Ownership

Company	Insider Ownership
AXGN AxoGen	2.44%
BBNX Beta Bionics	5.30%
LMAT LeMaitre Vascular	7.40%
PLSE Pulse Biosciences	74.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXGN AxoGen	450	53.76 million	52.45 million	Optionable
BBNX Beta Bionics	294	44.99 million	42.61 million	N/A
LMAT LeMaitre Vascular	490	22.85 million	21.16 million	Optionable
PLSE Pulse Biosciences	140	69.21 million	18.00 million	Optionable

BBNX, PLSE, LMAT, and AXGN Headlines

Recent News About These Companies

Pulse Biosciences to Present at Canaccord Genuity’s 46th Annual Growth Conference

July 30 at 12:55 AM | caledonianrecord.comC

Pulse Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference

July 30 at 4:05 PM | businesswire.com

Pulse Biosciences (PLSE) Expected to Release Earnings on Thursday

July 30 at 7:55 AM | marketbeat.com

Pulse Biosciences Surpasses Enrollment Midpoint in NANOPULSE-AF IDE Pivotal Study

July 29 at 8:33 AM | aol.comA

Pulse Biosciences (NASDAQ:PLSE) Hits New 12-Month High - What's Next?

July 28, 2026 | marketbeat.com

Pulse Biosciences (NASDAQ:PLSE) Shares Up 9.4% - Here's Why

July 27, 2026 | marketbeat.com

This little-known biotech stock just hit a new 5-year high

July 24, 2026 | msn.com

Pulse Biosciences (NASDAQ:PLSE) Reaches New 12-Month High - Still a Buy?

July 22, 2026 | marketbeat.com

Pulse Biosciences Schedules Second Quarter 2026 Financial Results Conference Call for August 6, 2026

July 21, 2026 | businesswire.com

Mizuho Securities Keeps Their Buy Rating on Pulse Biosciences (PLSE)

July 13, 2026 | theglobeandmail.com

Pulse Biosciences (NASDAQ:PLSE) Sees Large Volume Increase - Should You Buy?

July 9, 2026 | marketbeat.com

What Do Pulse Biosciences’ New Equity Awards Reveal About Executive Compensation Trends?

June 15, 2026 | kalkinemedia.comK

What Could New Equity Awards Signal for Pulse Biosciences’ Ongoing Growth Efforts?

June 15, 2026 | kalkinemedia.comK

Pulse Biosciences Shareholders Approve Board and Auditor Slate

June 12, 2026 | tipranks.com

Pulse Biosciences, Inc. (PLSE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

June 10, 2026 | seekingalpha.com

Pulse Biosciences Updates 2026 Cardiac Ablation Strategy

June 10, 2026 | theglobeandmail.com

Pulse Bio to redeem remaining common stock warrants

June 10, 2026 | seekingalpha.com

Did New Analyst Coverage and Insider Buying Just Shift Pulse Biosciences' (PLSE) Investment Narrative?

June 9, 2026 | finance.yahoo.com

Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026

May 27, 2026 | businesswire.com

Here's Why Pulse Biosciences, Inc (PLSE) is a Great Momentum Stock to Buy

May 26, 2026 | zacks.com

Why Pulse Biosciences, Inc.’s (PLSE) Stock Is Down 6.55%

May 16, 2026 | aaii.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBNX, PLSE, LMAT, and AXGN Company Descriptions

AxoGen NASDAQ:AXGN

$42.21 +0.86 (+2.08%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$40.30 -1.91 (-4.52%)

As of 07/31/2026 07:58 PM Eastern

AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.

Beta Bionics NASDAQ:BBNX

$12.83 -1.44 (-10.09%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$12.82 -0.01 (-0.08%)

As of 07/31/2026 07:38 PM Eastern

Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.

LeMaitre Vascular NASDAQ:LMAT

$101.32 -0.87 (-0.85%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$101.15 -0.17 (-0.17%)

As of 07/31/2026 07:34 PM Eastern

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

Pulse Biosciences NASDAQ:PLSE

$35.13 +0.09 (+0.26%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$35.38 +0.25 (+0.70%)

As of 07/31/2026 07:58 PM Eastern

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BBNX, PLSE, LMAT, and AXGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BBNX, PLSE, LMAT, and AXGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BBNX, PLSE, LMAT, and AXGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBNX, PLSE, LMAT, and AXGN Company Descriptions

AxoGen NASDAQ:AXGN

Beta Bionics NASDAQ:BBNX

LeMaitre Vascular NASDAQ:LMAT

Pulse Biosciences NASDAQ:PLSE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BBNX, PLSE, LMAT, and AXGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BBNX, PLSE, LMAT, and AXGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BBNX, PLSE, LMAT, and AXGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBNX, PLSE, LMAT, and AXGN Company Descriptions

AxoGen NASDAQ:AXGN

Beta Bionics NASDAQ:BBNX

LeMaitre Vascular NASDAQ:LMAT

Pulse Biosciences NASDAQ:PLSE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools